NeuroSense Therapeutics Revenue

Biotechnology Research • Cambridge, Massachusetts, United States • 21-50 Employees

NeuroSense Therapeutics revenue & valuation

Annual revenue	$2,737,760
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$8,800,000
Total funding	$15,100,000

Key Contacts at NeuroSense Therapeutics

Alon Ben-Noon

Ceo & Co-Founder

Miri Nadler Milbauer

Director Of Regulatory Affairs

Niva Russek- Blum

Chief Technology Officer

Racheli Gueta

Director Clinical Development

Noa Shabtay

Ragulatory Affairs Director

Company overview

Headquarters	1 Broadway, Cambridge, Massachusetts 02142, US
Phone number	+1097996183
Website	neurosense-tx.com
NAICS	541714
Keywords	ALS, Biopharmaceuticals, Neurodegenerative Diseases, Drug Development, CNS, Parkinson'S Disease, Alzheimer'S Disease, MND, Lou Gehrig'S Disease, Novel Treatment
Founded	2017
Employees	21-50
Socials

NeuroSense Therapeutics Email Formats

NeuroSense Therapeutics uses 2 email formats. The most common is {first name} (e.g., john@neurosense-tx.com), used 52.2% of the time.

Format	Example	Percentage
{first name}	john@neurosense-tx.com	52.2%
{first initial}	j@neurosense-tx.com	47.8%

About NeuroSense Therapeutics

Advancing research, development and therapy for ALS and additional CNS indications. NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) is a clinical stage Biotech company focusing on the development of a ground-breaking treatment for ALS patients, as well as other neurodegenerative diseases. Currently in conducting a Phase 2b, double-blind, randomized, placebo controlled clinical study in ALS patients globally. $NRSN

Employees by Management Level

Total employees: 21-50

Seniority

Employees

C-Suite

Manager

Director

Employees by Department

NeuroSense Therapeutics has 13 employees across 9 departments.

Departments

Number of employees

Funding Data

Explore NeuroSense Therapeutics's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount
2023-07-22	14	$4,500,000
2024-05-10	14	$4,500,000
2024-09-06	14	$600,000
2025-01-02	14	$5,000,000
2025-10-04	14	$500,000

Funding Insights

$15,100,000

Total funding amount

$500,000

Most recent funding amount

Number of funding rounds

NeuroSense Therapeutics Tech Stack

Discover the technologies and tools that power NeuroSense Therapeutics's digital infrastructure, from frameworks to analytics platforms.

reCAPTCHA

Security

jQuery UI

JavaScript libraries

Hello Elementor

WordPress themes

Elementor

Page builders

jQuery Migrate

JavaScript libraries

Twitter Emoji

Font scripts

jQuery

JavaScript libraries

PHP

Programming languages

WordPress

Blogs

MailChimp

Google Analytics

Analytics

Yoast SEO

SEO

Frequently asked questions

NeuroSense Therapeutics is located in Cambridge, Massachusetts, US.

You can reach NeuroSense Therapeutics at +1097996183.

NeuroSense Therapeutics generates an estimated annual revenue of $2,737,760. This revenue figure reflects the company's market position and business performance in its industry.

NeuroSense Therapeutics has an estimated valuation of $8,800,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

NeuroSense Therapeutics was founded in 2017, making it 9 years old. The company has established itself as a significant player in its industry over this time.

NeuroSense Therapeutics has approximately 21-50 employees. The company continues to grow its workforce to support its business operations and expansion.

NeuroSense Therapeutics has raised a total of $15,100,000 across 5 funding rounds. This investment has helped the company grow and expand its operations.

Key Contacts at NeuroSense Therapeutics

Alon Ben-Noon

Ceo & Co-Founder

Miri Nadler Milbauer

Director Of Regulatory Affairs

Niva Russek- Blum

Chief Technology Officer

Racheli Gueta

Director Clinical Development

Noa Shabtay

Ragulatory Affairs Director

4.8